MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Relypsa Company Profile (NASDAQ:RLYP)

Consensus Ratings for Relypsa (NASDAQ:RLYP) (?)
Ratings Breakdown: 1 Sell Rating(s), 2 Hold Rating(s), 12 Buy Rating(s)
Consensus Rating:Buy (Score: 2.73)
Consensus Price Target: $35.46 (91.79% upside)

Analysts' Ratings History for Relypsa (NASDAQ:RLYP)
Show:
DateFirmActionRatingPrice TargetActions
6/28/2016Stifel NicolausReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016BTIG ResearchReiterated RatingBuy$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2016MizuhoReiterated RatingNeutral$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/16/2016Cantor FitzgeraldReiterated RatingBuy$41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/16/2016WedbushReiterated RatingOutperform -> Outperform$51.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Morgan StanleyDowngradeEqual Weight -> Underweight$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016HC WainwrightReiterated RatingBuy$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016Oppenheimer Holdings Inc.Reiterated RatingOutperform$36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/29/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/17/2016Brean CapitalReiterated RatingBuy$26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/17/2016Citigroup Inc.Reiterated RatingBuy$30.00 -> $25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/1/2016Raymond James Financial Inc.Initiated CoverageMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2016Bank of America Corp.Reiterated RatingBuy$32.00 -> $29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2015GuggenheimInitiated CoverageBuy$46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/27/2015Nomura Holdings Inc.Reiterated RatingOutperform$75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/1/2014 forward)
Earnings History for Relypsa (NASDAQ:RLYP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/4/2016Q1($1.46)($1.26)$6.88 million$12.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2016Q415($1.35)($1.40)$7.37 million$11.96 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2015Q3($0.89)($1.24)$6.67 million$6.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015($0.95)($0.95)$0.01 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015($0.87)($0.78)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2015Q414($0.68)($0.80)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014($0.61)($0.57)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014($0.57)($0.51)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014($0.56)($0.54)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2014Q413($0.50)($0.68)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Relypsa (NASDAQ:RLYP)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($1.61)($1.42)($1.52)
Q2 20162($1.53)($1.43)($1.48)
Q3 20162($1.65)($1.47)($1.56)
Q4 20162($1.65)($1.40)($1.53)
Q1 20171($1.65)($1.65)($1.65)
Q2 20171($1.64)($1.64)($1.64)
Q3 20171($1.62)($1.62)($1.62)
Q4 20171($1.59)($1.59)($1.59)
(Data provided by Zacks Investment Research)
Dividend History for Relypsa (NASDAQ:RLYP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Relypsa (NASDAQ:RLYP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/7/2016David W J McgirrDirectorSell1,013$19.34$19,591.42View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2016Kristine M BallCFOBuy7,000$12.15$85,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016Thomas J SchuetzDirectorBuy30,000$13.39$401,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/31/2015Wilhelm StahlSVPSell20,000$28.53$570,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2015Orbimed Advisors LlcMajor ShareholderSell500,000$27.18$13,590,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2015Lance BermanSVPSell750$29.50$22,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2015John A. OrwinCEOSell15,000$28.28$424,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2015Lance BermanSVPSell30,000$29.78$893,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2015John A. OrwinCEOSell40,000$25.00$1,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/22/2015Orbimed Advisors LlcMajor ShareholderBuy500,000$12.56$6,280,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015John A OrwinCEOSell5,000$24.84$124,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Lance BermanSVPSell710$24.77$17,586.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Ronald A KrasnowInsiderSell522$24.75$12,919.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2015Thomas J SchuetzDirectorSell1,000$34.57$34,570.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015John A OrwinCEOSell33,555$36.42$1,222,073.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2015Orbimed Advisors LlcMajor ShareholderSell1,457,551$34.13$49,746,215.63View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2015Klaus R Dr VeitingerDirectorSell5,834$36.06$210,374.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/10/2015Klaus R Dr VeitingerDirectorSell5,832$35.35$206,161.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2015Kristine M BallCFOSell3,519$40.68$143,152.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/27/2015Ronald A KrasnowInsiderSell10,348$39.00$403,572.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/24/2015Lance BermanSVPSell5,000$38.19$190,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/24/2015Ronald A KrasnowInsiderSell10,000$39.00$390,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2015Klaus R Dr VeitingerDirectorSell5,834$32.12$187,388.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2015Claire LockeyInsiderSell5,000$35.00$175,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2015Kristine M BallCFOSell3,000$36.00$108,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/14/2015Ronald A KrasnowInsiderSell5,000$33.58$167,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Klaus R Dr VeitingerDirectorSell5,834$32.33$188,613.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/12/2014Klaus R Dr VeitingerDirectorSell14,169$32.16$455,675.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/20145Am Partners Iii, LlcMajor ShareholderSell589,637$30.04$17,712,695.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2014Claire LockeyInsiderSell8,000$30.00$240,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Lance BermanSVPSell30,000$25.00$750,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2014Klaus R Dr VeitingerDirectorSell2,500$19.34$48,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2014Lance BermanSVPSell5,000$22.00$110,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2014Orbimed Advisors LlcMajor ShareholderSell94,000$25.27$2,375,380.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/20145Am Partners Ii, LlcMajor ShareholderSell612,540$26.03$15,944,416.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2014Klaus R Dr VeitingerDirectorSell4,167$23.00$95,841.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/29/2014Wilhelm StahlSVPSell15,785$25.29$399,202.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/20145Am Partners Ii, LlcMajor ShareholderSell433,000$26.51$11,478,830.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Lance BermanSVPSell20,000$25.89$517,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/11/2014Klaus R Dr VeitingerDirectorSell4,167$27.73$115,550.91View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/24/2014Lance BermanSVPSell45,000$23.92$1,076,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2014Klaus R Dr VeitingerDirectorSell4,167$23.12$96,341.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/20135Am Partners Iii, LlcMajor ShareholderBuy372,692$11.00$4,099,612.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2013John A OrwinCEOBuy15,000$11.00$165,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2013Leaf Ventures I L.P. NewInsiderBuy185,978$11.00$2,045,758.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2013Scott M RocklageDirectorBuy363,328$11.00$3,996,608.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Relypsa (NASDAQ:RLYP)
DateHeadline
07/01/16 06:10 PMJhl Capital Group LLC Increased Relypsa INC (NASDAQ:RLYP) by $9.75 Million as Shares Declined - Engelwood Daily
06/30/16 06:24 PMOccam's Razor And The Bull Case On Relypsa - Seeking Alpha
06/30/16 06:24 PMRelypsa Inc. (RLYP) Jumps 9.88% on June 28 - Equities.com
06/29/16 06:03 PMStifel Reiterates Bullish View on Relypsa (RLYP) as Veltassa Continues to Show Significant Competitive Differentiation
06/29/16 08:54 AMBiogen Inc (NASDAQ:BIIB) & Relypsa Inc (NASDAQ:RLYP) Healthcare Stocks to Watch - Wall Street 24
06/29/16 08:54 AMRelypsa, Inc. (NASDAQ:RLYP) Company Rating and Target Watch - Telanagana Press
06/28/16 06:03 PMHealthCare Royalty Partners Commits $205 Million to New Investments Over the First Half of 2016
06/28/16 06:03 PMRelypsa (RLYP) Announces Publication of Significant Veltassa Phase 3 Data in CKD for RAAS Inhibitor Patients
06/28/16 07:01 AMCompany Update (NASDAQ:RLYP): Relypsa Inc Announces Results of Pre-Specified Exploratory Analysis of Phase 3 ... - Smarter Analyst
06/27/16 03:17 PM4:17 pm Relypsa announces results of a pre-specified exploratory analysis of the Phase 3 OPAL-HK trial of Veltassa for oral suspension were published online by Kidney International -
06/27/16 03:16 PMResults of Pre-Specified Exploratory Analysis of Phase 3 OPAL-HK Study Evaluating Effects of Veltassa on Blood Pressure and Aldosterone Published in Kidney International - [GlobeNewswire] - REDWOOD CITY, Calif., June 27, 2016-- Relypsa, Inc., a biopharmaceutical company, today announced that results of a pre-specified exploratory analysis of the Phase 3 OPAL-HK trial of Veltassa ® for oral ...
06/27/16 03:12 PMRELYPSA INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/27/16 02:16 PMShare Update and Earnings Review for Relypsa, Inc. (NASDAQ:RLYP) - Press Telegraph
06/27/16 02:16 PMThe Relypsa Rumble, Part 1: The Bear Case - Seeking Alpha
06/25/16 09:53 AMRelypsa Inc. (RLYP) Jumps 5.36% on June 23 - Equities.com
06/22/16 06:06 PMRelypsa, Inc. (NASDAQ:RLYP) Stock Momentum at Critical Inflection Point - CML News
06/21/16 10:28 AMAnalysts and Technical Insights on Relypsa Inc (NASDAQ:RLYP) - Street Report
06/20/16 07:42 AMTwo Movers within Analysts Observation: Johnson & Johnson (NYSE:JNJ) , Relypsa, Inc. (NASDAQ:RLYP) - Street Updates
06/20/16 07:42 AMHC Stocks Updates: Anacor Pharmaceuticals Inc (NASDAQ:ANAC), Relypsa Inc (NASDAQ:RLYP) - share market updates (press release)
06/20/16 07:42 AMRelypsa: Bears Bring Nothing New To The Table - Seeking Alpha
06/17/16 08:51 AMHC Stocks Newsbeat: Relypsa Inc (NASDAQ:RLYP), UnitedHealth Group Inc (NYSE:UNH) - share market updates (press release)
06/17/16 08:51 AMA Rebuttal To A Short Thesis On Relypsa - Seeking Alpha
06/16/16 06:22 PMEye Catching Stock: Relypsa, Inc. (NASDAQ:RLYP) - News Oracle
06/16/16 06:22 PMAnalysts Rating Alert: CVS Health Corporation (NYSE:CVS) , Relypsa, Inc. (NASDAQ:RLYP) - Street Updates
06/16/16 06:22 PMRelypsa Inc. (RLYP) Drops 6.11% on June 15 - Equities.com
06/16/16 10:27 AMRelypsa, Inc. (RLYP) – Wedbush Holds Rating And Sets New Price Target
06/16/16 10:27 AMMay Relypsa (RLYP) Veltassa Figures Point to Continued Uptake - Wedbush
06/16/16 08:28 AMHere’s Why Amsurg, Relypsa, FireEye, and Two More Stocks Are Trending on Thursday -
06/14/16 10:55 AMStock to keep an eye on: Relypsa, Inc. (NASDAQ:RLYP) - News Oracle
06/13/16 12:15 PMRelypsa: How The Bulls and Bears are Both Right -
06/13/16 09:05 AMAnalysts Trends to Watch: Astrazeneca PLC (NYSE:AZN) , Relypsa, Inc. (NASDAQ:RLYP) - Street Updates
06/13/16 09:05 AMHC Stocks Growth: Horizon Pharma PLC (NASDAQ:HZNP), Relypsa Inc (NASDAQ:RLYP) - share market updates (press release)
06/10/16 09:11 AMEarnings Surprise in Focus: Relypsa, Inc. (NASDAQ:RLYP) - Investor Newswire
06/09/16 06:38 PMAnalyst Opinions on: Unum Group (NYSE:UNM), Relypsa, Inc. (NASDAQ:RLYP) - Beacon Chronicle
06/09/16 09:49 AMStreetSweeper On Relypsa: 8 Reasons 'We Wouldn't Run Away & Join This Circus' -
06/08/16 06:38 PMStock under Radar: Relypsa, Inc. (NASDAQ:RLYP) - News Oracle
06/08/16 06:38 PMRELYPSA INC. (NASDAQ:RLYP) Financial Condition Compared to S&P 500 - CML News
06/08/16 09:09 AMHC Stocks Highlights: Relypsa Inc (NASDAQ:RLYP), Celgene Corporation (NASDAQ:CELG) - share market updates (press release)
06/07/16 06:22 PMAnalysts Review of Stocks: Abbott Laboratories (NYSE:ABT) , Relypsa, Inc. (NASDAQ:RLYP) - Street Updates
06/07/16 06:05 AMRelypsa downgraded by Morgan Stanley -
06/06/16 06:06 PMNotable Analysts Recommendation to Monitor: Relypsa, Inc. (NASDAQ:RLYP) , Endologix, Inc. (NASDAQ:ELGX) - Street Updates
06/06/16 06:06 PMTrending Stock Analysis: Relypsa, Inc. (NASDAQ:RLYP) - News Oracle
06/06/16 06:06 PMStock Update (NASDAQ:RLYP): Relypsa Inc Announces New Employment Inducement Grants - Smarter Analyst
06/06/16 03:15 PMRelypsa Announces New Employment Inducement Grants - [GlobeNewswire] - REDWOOD CITY, Calif., June 06, 2016-- Relypsa, Inc., a biopharmaceutical company, today announced that on June 1, 2016, the compensation committee of the company’ s board of directors granted 2 new employees ...
06/06/16 09:50 AMNotable Analysts Recommendation to Monitor: Relypsa, (RLYP) , Endologix, (ELGX) - Street Updates
06/06/16 09:50 AMComprehensive Analysis of: Relypsa, Inc. (NASDAQ:RLYP), Synchrony Financial (NYSE:SYF) - Beacon Chronicle
06/04/16 06:13 PMRelypsa Inc (RLYP): Veltassa to Rule the Multi-Billion Dollar Hyperkalemia Market - Bidness ETC
06/04/16 09:06 AMRelypsa Inc (RLYP) Stock Rating Reaffirmed by HC Wainwright - Let Me Know About This
06/03/16 09:04 AMRELYPSA, INC. (NASDAQ:RLYP) FINANCIAL CONDITION REPORT - CML News
06/03/16 09:04 AMRelypsa Inc. (RLYP) is Trading Higher on Unusual Volume for June 01 - Equities.com
About Relypsa

Relypsa logoRelypsa, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of polymer-based drugs to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patients' lives and even be life-threatening. The Company's first drug candidate is Veltassa (patiromer) for oral suspension, or Veltassa, for the treatment of hyperkalemia. Hyperkalemia is a life threatening condition defined as abnormally elevated levels of potassium in the blood. Veltassa is a non-absorbed, potassium binding polymer. The active ingredient in Veltassa is a cross-linked polymeric bead that includes calcium as a counterion. Veltassa is a dry powder that is combined with small amounts of water prior to administration. Veltassa is packaged in single-use packets containing approximately 8.4 grams, 16.8 grams or 25.2 grams patiromer, with a recommended starting dose of approximately 8.4 grams patiromer once daily.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RLYP
  • CUSIP:
Key Metrics:
  • Previous Close: $18.49
  • 50 Day Moving Average: $17.46
  • 200 Day Moving Average: $18.29
  • P/E Ratio: N/A
  • P/E Growth: -1.30
  • Market Cap: $827.37M
  • Current Quarter EPS Consensus Estimate: $-5.91 EPS
Additional Links:
Relypsa (NASDAQ:RLYP) Chart for Friday, July, 1, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha